Mitomycin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Mitomycin: Osteoclastic giant cell tumor of pancreas
One-Sentence Summary
Mitomycin is a cytotoxic anticancer injection whose original indication, as recorded in the knowledge graph, is pancreatic adenocarcinoma. The TxGNN model predicts it may be effective for osteoclastic giant cell tumor of the pancreas, but there are 0 clinical trials and 0 publications directly studying this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Osteoclastic giant cell tumor of pancreas |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (16 of 16) – CDSCO approval status is not included in this data |
| Number of Listed Products | 16 (valid: 16) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, mitomycin is a DNA cross-linking cytotoxic agent. Its use in pancreatic adenocarcinoma is recorded in the knowledge graph, and mechanistically it may be applicable to other pancreatic exocrine tumours.
The predicted disease is a rare pancreatic tumour variant. The model’s link appears to come from shared pancreatic tumour biology and from the recorded adenocarcinoma relation. No trial or publication addresses this tumour directly, so the link remains unverified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the predicted disease.
Some other pancreatic tumour terms in the prediction list have only indirect papers, such as a 2005 case report of pseudomyxoma peritonei with an intraductal papillary mucinous neoplasm (PMID 15983445). None of them studies osteoclastic giant cell tumor of the pancreas, so they do not raise its evidence level.
India Market Information
There are 16 valid single-ingredient registrations, all injections. The records contain no approved-indication text. The main ones are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 135815 | Mitomycin 10mg Injection (Biochem Pharmaceutical Industries) | Vial of 1 injection | Not stated in the records |
| 168193 | Oncocin 10mg Injection (Chandra Bhagat Pharma) | Vial of 1 injection | Not stated in the records |
| 135703 | Mitomycin C 2mg Injection (Biochem Pharmaceutical Industries) | Vial of 2 ml injection | Not stated in the records |
| 138509 | Mito 10mg Injection (Neon Laboratories) | Vial of 1 injection | Not stated in the records |
| 140054 | Mitocin 10mg Injection (Cadila Pharmaceuticals) | Vial of 1 injection | Not stated in the records |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA cross-linking agent) |
| Myelosuppression Risk | High (the knowledge graph records thrombocytopenia, leukopenia and anaemia as contraindication-related conditions) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count with platelets, renal function, signs of haemolytic-uremic syndrome, cardiac status |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindication-related conditions (knowledge graph, not label text): kidney disease, thrombocytopenia, blood coagulation disease, anaemia, leukopenia, hemolytic-uremic syndrome, congestive heart failure, heart failure, stomatitis, and pyoureter.
- Drug Interactions: 193 interactions are recorded. Major-level ones among those listed include deferiprone and samarium (153Sm) lexidronam. Moderate-level ones include palifermin, strontium chloride Sr-89 and fostamatinib. Many others have an unclassified severity, including warfarin, dexamethasone and prednisone.
Please refer to the package insert for full warnings and contraindications, as label text was not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no trial or publication that studies this disease. That puts it at evidence level L5. The drug is a toxic cytotoxic agent, and label warnings were not available for review.
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indications for the Indian registrations
- Mechanism of action data
- Disease-specific literature or trial data on mitomycin in this rare tumour
- Clinical review of whether cytotoxic therapy is appropriate for this tumour type
- Route and dosing compatibility assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.